Christopher Michael Pieczonka
Research Subjects
Christopher Michael Pieczonka has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Neal D. Shore
START Carolinas/Carolina Urologic Research Center, Myrtle Beach, USA
38 shared publications - Lawrence Ivan Karsh
The Urology Center of Colorado, Denver, Colorado
36 shared publications - Emmanuel S. Antonarakis
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
34 shared publications - Daniel Peter Petrylak
Smilow Cancer Center, Yale School of Medicine, New Haven, CT
33 shared publications - David I. Quinn
10Department of Medical Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California
33 shared publications - Helen M. Wilfehrt
Dendreon Pharmaceuticals, LLC, Seattle, Washington
33 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 3 In vivo cellular and humoral responses through 52 weeks are illustrated here.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 3 In vivo cellular and humoral responses through 52 weeks are illustrated here.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 1 Analysis of Survival by Baseline Median PSA across the two studies using the study-specific median and quartiles.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 1 Analysis of Survival by Baseline Median PSA across the two studies using the study-specific median and quartiles.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 2. Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 2. Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Data for Antonarakis et al
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Data for Antonarakis et al
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Purpose:We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed to study the impact of sequential or concurrent administration of androgen receptor–targeting agents (ARTAs) on sipuleucel-T immune response and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:Sipuleucel-T was administered per current prescribing information. Results from STRIDE are presented together with updated STAMP results. Survival status of patients was updated using demographic information to query the National Death Index (NDI). Kaplan–Meier methodology was used to analyze survival.Results:Updated data reduced patient censoring in each study compared with the original analyses; the 95% confidence intervals (CIs) for OS are now estimable. Updated median OS (95% CI) is 33.3 (24.1–40.7) months for STAMP and 32.5 (26.0–45.1) months for STRIDE. There was no notable impact on median OS [HR, 0.727 (0.458–1.155); P = 0.177, reference = STRIDE]. OS with sequential administration was similar to concurrent administration [NDI update: HR, 0.963 (0.639–1.453); P = 0.845, reference = concurrent arm]. Sipuleucel-T potency, measured as antigen-presenting cell (APC) activation, was higher in subsequent infusions compared with the first infusion. Humoral responses (IgG + IgM antibody titers) to PA2024 and prostatic acid phosphatase were significantly elevated versus baseline. No new safety signals were observed.Conclusions:Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Purpose:We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed to study the impact of sequential or concurrent administration of androgen receptor–targeting agents (ARTAs) on sipuleucel-T immune response and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:Sipuleucel-T was administered per current prescribing information. Results from STRIDE are presented together with updated STAMP results. Survival status of patients was updated using demographic information to query the National Death Index (NDI). Kaplan–Meier methodology was used to analyze survival.Results:Updated data reduced patient censoring in each study compared with the original analyses; the 95% confidence intervals (CIs) for OS are now estimable. Updated median OS (95% CI) is 33.3 (24.1–40.7) months for STAMP and 32.5 (26.0–45.1) months for STRIDE. There was no notable impact on median OS [HR, 0.727 (0.458–1.155); P = 0.177, reference = STRIDE]. OS with sequential administration was similar to concurrent administration [NDI update: HR, 0.963 (0.639–1.453); P = 0.845, reference = concurrent arm]. Sipuleucel-T potency, measured as antigen-presenting cell (APC) activation, was higher in subsequent infusions compared with the first infusion. Humoral responses (IgG + IgM antibody titers) to PA2024 and prostatic acid phosphatase were significantly elevated versus baseline. No new safety signals were observed.Conclusions:Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.
- Open Access
- 1 November 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (3) , 1-4
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Background DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Subjects/Methods This prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily. Results Darolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS. Conclusions These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.
- 1 November 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (3) , 1-4
Open AccessDARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Background DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Subjects/Methods This prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily. Results Darolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS. Conclusions These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.
- Open Access
- 22 September 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (2) , 346-352
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients
Background Although germline genetic testing can inform medical management for patients with prostate cancer (PCa), data are limited regarding patient-reported outcomes (PROs) after germline genetic testing for PCa. Recall and comprehension of germline genetic testing results, uptake of post-test clinical recommendations, and psychological impact of germline genetic testing among patients with PCa were evaluated. Methods This is a secondary analysis of data from the PROCLAIM trial. PROs were analyzed overall and by germline genetic testing results. Differences between groups were determined by two-tailed Fisher’s exact test with significance set at p < 0.05. Results Among 494 patients with informative survey responses, 60% and 71% accurately recalled and interpreted their germline genetic testing results, respectively, with the highest rates among patients with negative results and the lowest among those with variant of uncertain significance-only (VUS) results. Among 42/55 (76%) patients with positive results for whom clinicians made germline genetic testing-informed recommendations, 39 (93%) completed or planned to complete >1 clinical recommendation. Conversely, no further recommendations were made for 160/221 (72%) and 211/218 (97%) patients with VUS and negative results, respectively. However, 57% (213/371) of these patients indicated that they or their family members intended to pursue clinical management strategies that were not recommended by their clinicians. Of the patients who responded to the survey, >90% of patients reported no post-germline genetic testing increase in their level of concern for themselves or their family members. Conclusion germline genetic testing for patients with PCa did not cause appreciable psychological harm to the tested patients. Furthermore, patients with positive results had a high uptake of clinician-recommended management strategies. Of note, there were inconsistencies in the understanding of VUS results, with some clinicians making recommendations not warranted by personal/family history; conversely, some patients pursued management strategies not recommended by their clinicians. This suggests that educational efforts are needed in the communication of germline genetic testing results and clinical recommendations to patients.
- 22 September 2025
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (2) , 346-352
Open AccessUsing patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients
Background Although germline genetic testing can inform medical management for patients with prostate cancer (PCa), data are limited regarding patient-reported outcomes (PROs) after germline genetic testing for PCa. Recall and comprehension of germline genetic testing results, uptake of post-test clinical recommendations, and psychological impact of germline genetic testing among patients with PCa were evaluated. Methods This is a secondary analysis of data from the PROCLAIM trial. PROs were analyzed overall and by germline genetic testing results. Differences between groups were determined by two-tailed Fisher’s exact test with significance set at p < 0.05. Results Among 494 patients with informative survey responses, 60% and 71% accurately recalled and interpreted their germline genetic testing results, respectively, with the highest rates among patients with negative results and the lowest among those with variant of uncertain significance-only (VUS) results. Among 42/55 (76%) patients with positive results for whom clinicians made germline genetic testing-informed recommendations, 39 (93%) completed or planned to complete >1 clinical recommendation. Conversely, no further recommendations were made for 160/221 (72%) and 211/218 (97%) patients with VUS and negative results, respectively. However, 57% (213/371) of these patients indicated that they or their family members intended to pursue clinical management strategies that were not recommended by their clinicians. Of the patients who responded to the survey, >90% of patients reported no post-germline genetic testing increase in their level of concern for themselves or their family members. Conclusion germline genetic testing for patients with PCa did not cause appreciable psychological harm to the tested patients. Furthermore, patients with positive results had a high uptake of clinician-recommended management strategies. Of note, there were inconsistencies in the understanding of VUS results, with some clinicians making recommendations not warranted by personal/family history; conversely, some patients pursued management strategies not recommended by their clinicians. This suggests that educational efforts are needed in the communication of germline genetic testing results and clinical recommendations to patients.
- Open Access
- 27 August 2025
- Published by Springer Nature in Research Square
Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology
Background Sipuleucel-T, approved for metastatic castration-resistant prostate cancer (mCRPC) in 2010, improves survival, but real-world outcomes data are limited. We compared baseline characteristics and real-world overall survival (rwOS) of patients treated with and without sipuleucel-T for mCRPC. Methods This multicenter, retrospective observational study analyzed electronic medical records from United States community urology clinics. Men aged ≥ 18 years diagnosed with mCRPC between January 2010 and May 2019 were divided into 2 groups based on whether they received sipuleucel-T. Propensity score matching (PSM) was used to balance the cohorts by age, race, region, prostate-specific antigen (PSA) level, and Gleason score. Results Among 11 265 patients, 47% received sipuleucel-T. They were younger, had lower PSA levels, and better performance scores than those who did not receive it. Median follow-up was 3 years for treated and 1 year for untreated patients. Sipuleucel-T recipients had markedly better 5-year survival rates (28% vs 12%) and lived a median of 20 months longer (44 vs 24 months; P < .001). Black/African American patients had the highest 5-year survival (24%) compared with White (20%) or other groups (17%). After PSM, the median rwOS was 43 months with sipuleucel-T and 25 months without it, with an 18-month survival advantage (hazard ratio 1.66; 95% CI 1.54–1.78). Conclusions Sipuleucel-T was associated with significantly improved mCRPC survival in real-world settings, especially among Black/African American patients. Findings are subject to limitations, including selection bias and unmeasured confounding, but reinforce the therapeutic and life-prolonging benefit of sipuleucel-T.
- 27 August 2025
- Published by Springer Nature in Research Square
Open AccessMetastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology
Background Sipuleucel-T, approved for metastatic castration-resistant prostate cancer (mCRPC) in 2010, improves survival, but real-world outcomes data are limited. We compared baseline characteristics and real-world overall survival (rwOS) of patients treated with and without sipuleucel-T for mCRPC. Methods This multicenter, retrospective observational study analyzed electronic medical records from United States community urology clinics. Men aged ≥ 18 years diagnosed with mCRPC between January 2010 and May 2019 were divided into 2 groups based on whether they received sipuleucel-T. Propensity score matching (PSM) was used to balance the cohorts by age, race, region, prostate-specific antigen (PSA) level, and Gleason score. Results Among 11 265 patients, 47% received sipuleucel-T. They were younger, had lower PSA levels, and better performance scores than those who did not receive it. Median follow-up was 3 years for treated and 1 year for untreated patients. Sipuleucel-T recipients had markedly better 5-year survival rates (28% vs 12%) and lived a median of 20 months longer (44 vs 24 months; P < .001). Black/African American patients had the highest 5-year survival (24%) compared with White (20%) or other groups (17%). After PSM, the median rwOS was 43 months with sipuleucel-T and 25 months without it, with an 18-month survival advantage (hazard ratio 1.66; 95% CI 1.54–1.78). Conclusions Sipuleucel-T was associated with significantly improved mCRPC survival in real-world settings, especially among Black/African American patients. Findings are subject to limitations, including selection bias and unmeasured confounding, but reinforce the therapeutic and life-prolonging benefit of sipuleucel-T.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 2 . Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Fig 2 . Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Data for Antonarakis et al
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Supplementary Data for Antonarakis et al